HER2-Negative Breast Cancer Terminated Phase 2 Trials for Goserelin (DB00014)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01368263Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast CancerTreatment